A short post-today, with important implications:
- Big news this week from the American College of Cardiology conference! The results of the FOURIER trial were released on-line in the New England Journal of Medicine. In this landmark trial, Evolocumab, a PCSK9 inhibitor already demonstrated to be highly effective at reducing LDL cholesterol levels and atheroma volume (GLAGOV-reference below), was found to be associated with improved cardiovascular outcomes.
- Though important questions remain, the demonstrated clinical efficacy represents an important and potentially landmark step forward in the management of patients with high cholesterol.
- Click to view the study results and accompanying editorial.